Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
26.80
+0.89 (3.43%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Ultragenyx Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 125 | 421 | 174 | 213.58 | 132.94 | 307.58 |
Short-Term Investments | 167 | 259 | 436 | 363.63 | 614.82 | 432.61 |
Cash & Short-Term Investments | 292 | 680 | 610 | 577.21 | 747.76 | 740.2 |
Cash Growth | -40.11% | 11.47% | 5.68% | -22.81% | 1.02% | -38.40% |
Accounts Receivable | 200 | 158 | 122 | 73.39 | 40.45 | 28.43 |
Inventory | 59 | 52 | 45 | 33.97 | 26.77 | 16.23 |
Other Current Assets | 55 | 61 | 40 | 47.62 | 68.93 | 71.75 |
Total Current Assets | 606 | 951 | 817 | 732.18 | 883.9 | 856.6 |
Net Property, Plant & Equipment | 235 | 244 | 266 | 290.57 | 259.73 | 176.18 |
Other Intangible Assets | 172 | 176 | 178 | 166.27 | 160.11 | 130.79 |
Goodwill | 44 | 44 | 44 | 44.41 | 44.41 | 44.41 |
Long-Term Investments | 144 | 57 | 135 | 199.9 | 148.97 | 293.86 |
Other Long-Term Assets | 63 | 60 | 63 | 57.69 | 48.34 | 20.56 |
Total Assets | 1,264 | 1,532 | 1,503 | 1,491 | 1,545 | 1,522 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 39 | 31 | 39 | 42.11 | 43.27 | 17.14 |
Accrued Expenses | 221 | 265 | 241 | 196.49 | 204.68 | 145.56 |
Current Portion of Leases | - | 12 | 10 | 12.6 | 11.78 | 11.07 |
Unearned Revenue | - | - | - | - | 1.48 | 7.61 |
Other Current Liabilities | 91 | 76 | 54 | 29.24 | - | - |
Total Current Liabilities | 351 | 384 | 344 | 280.44 | 261.21 | 181.37 |
Long-Term Leases | - | 24 | 30 | 30.57 | 19.81 | 30.9 |
Other Long-Term Liabilities | 1,197 | 1,197 | 867 | 904.59 | 911.93 | 387.56 |
Total Long-Term Liabilities | 1,197 | 1,221 | 897 | 935.16 | 931.74 | 418.47 |
Total Liabilities | 1,548 | 1,605 | 1,241 | 1,216 | 1,193 | 599.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | - | 8 | 4 | 0.08 | 0.07 | 0.07 |
Treasury Stock | -10 | -8 | -4 | -0.43 | - | - |
Additional Paid-in Capital | 4,518 | 4,451 | 4,213 | 3,662 | 3,140 | 2,997 |
Accumulated Other Comprehensive Income | 10 | 1 | -1 | 1.08 | -6.57 | -1.4 |
Retained Earnings | -4,809 | -4,532 | -3,957 | -3,388 | -2,781 | -2,074 |
Total Common Shareholders' Equity | -291 | -80 | 255 | 275.41 | 352.49 | 922.56 |
Minority Interest | 7 | 7 | 7 | - | - | - |
Shareholders' Equity | -284 | -73 | 262 | 275.41 | 352.49 | 922.56 |
Total Liabilities & Equity | 1,264 | 1,532 | 1,503 | 1,491 | 1,545 | 1,522 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 36 | 40 | 43.17 | 31.59 | 41.97 |
Net Cash (Debt) | 292 | 644 | 570 | 534.04 | 716.17 | 698.23 |
Net Cash Growth | -35.30% | 12.98% | 6.73% | -25.43% | 2.57% | -39.46% |
Net Cash Per Share | 2.90 | 6.53 | 6.30 | 7.27 | 10.24 | 10.30 |
Book Value | -291 | -80 | 255 | 275.41 | 352.49 | 922.56 |
Book Value Per Share | -2.89 | -0.81 | 2.82 | 3.75 | 5.04 | 13.61 |
Tangible Book Value | -507 | -300 | 33 | 64.74 | 147.98 | 747.37 |
Tangible Book Value Per Share | -5.04 | -3.04 | 0.36 | 0.88 | 2.12 | 11.02 |